Xenon Pharmaceuticals Inc. (XENE)
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
Xenon Pharmaceuticals Q2 Earnings Call Highlights
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter.
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is progressing toward a Q3 2026 NDA filing. The company has a cash runway through 2029, supporting ongoing Phase 3 trials in MDD, bipolar depression, and pain, and is building a commercial infrastructure.
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
